| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 41 | 2022 | 64 | 5.110 |
Why?
|
| Pancreatic Neoplasms | 46 | 2023 | 341 | 4.200 |
Why?
|
| Pancreatitis, Acute Necrotizing | 23 | 2022 | 24 | 3.650 |
Why?
|
| Pancreatectomy | 36 | 2023 | 101 | 3.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 20 | 2023 | 111 | 2.130 |
Why?
|
| Postoperative Complications | 26 | 2023 | 1304 | 1.390 |
Why?
|
| Laparoscopy | 13 | 2021 | 491 | 1.270 |
Why?
|
| Pancreatic Ducts | 11 | 2020 | 30 | 1.270 |
Why?
|
| Adenocarcinoma | 15 | 2022 | 342 | 1.250 |
Why?
|
| Drainage | 15 | 2022 | 154 | 1.100 |
Why?
|
| Retrospective Studies | 76 | 2023 | 6627 | 1.060 |
Why?
|
| Pancreatic Fistula | 10 | 2021 | 18 | 1.030 |
Why?
|
| Adenocarcinoma, Mucinous | 9 | 2019 | 31 | 0.970 |
Why?
|
| Intestinal Fistula | 3 | 2020 | 10 | 0.870 |
Why?
|
| Middle Aged | 89 | 2022 | 17535 | 0.840 |
Why?
|
| Duodenal Diseases | 2 | 2020 | 15 | 0.830 |
Why?
|
| Sphincter of Oddi Dysfunction | 3 | 2023 | 3 | 0.790 |
Why?
|
| Pancreatic Diseases | 7 | 2015 | 39 | 0.790 |
Why?
|
| Mesenteric Veins | 2 | 2020 | 11 | 0.780 |
Why?
|
| Humans | 138 | 2023 | 63283 | 0.780 |
Why?
|
| Pancreatitis | 6 | 2023 | 97 | 0.750 |
Why?
|
| Female | 111 | 2022 | 32776 | 0.750 |
Why?
|
| Gallbladder | 12 | 2007 | 38 | 0.710 |
Why?
|
| Gallstones | 3 | 2020 | 25 | 0.710 |
Why?
|
| Patient Discharge | 3 | 2023 | 511 | 0.700 |
Why?
|
| Aged | 66 | 2022 | 14384 | 0.700 |
Why?
|
| Male | 93 | 2022 | 29799 | 0.690 |
Why?
|
| Nomograms | 1 | 2020 | 18 | 0.670 |
Why?
|
| Pancreas | 7 | 2019 | 150 | 0.660 |
Why?
|
| Vascular Fistula | 1 | 2020 | 8 | 0.660 |
Why?
|
| Crohn Disease | 2 | 2020 | 111 | 0.650 |
Why?
|
| Patient Readmission | 7 | 2023 | 430 | 0.640 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 78 | 0.640 |
Why?
|
| Adult | 60 | 2022 | 16771 | 0.630 |
Why?
|
| Venous Thrombosis | 5 | 2022 | 115 | 0.620 |
Why?
|
| Cholangiocarcinoma | 8 | 2012 | 31 | 0.590 |
Why?
|
| Choledochostomy | 1 | 2018 | 3 | 0.580 |
Why?
|
| Common Bile Duct | 1 | 2018 | 19 | 0.570 |
Why?
|
| Duodenum | 1 | 2018 | 42 | 0.560 |
Why?
|
| Pancreatic Cyst | 6 | 2018 | 24 | 0.560 |
Why?
|
| Hepatectomy | 7 | 2022 | 63 | 0.560 |
Why?
|
| Bile Duct Neoplasms | 7 | 2012 | 53 | 0.540 |
Why?
|
| Treatment Outcome | 36 | 2023 | 5647 | 0.540 |
Why?
|
| Carcinoma, Papillary | 6 | 2019 | 36 | 0.530 |
Why?
|
| Incidence | 19 | 2022 | 1375 | 0.500 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 5443 | 0.470 |
Why?
|
| Debridement | 5 | 2022 | 34 | 0.470 |
Why?
|
| Palliative Care | 8 | 2017 | 228 | 0.450 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2010 | 26 | 0.450 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2023 | 91 | 0.440 |
Why?
|
| Length of Stay | 15 | 2021 | 811 | 0.440 |
Why?
|
| Gastroparesis | 3 | 2019 | 8 | 0.410 |
Why?
|
| Obesity | 10 | 2022 | 1230 | 0.410 |
Why?
|
| Gallbladder Diseases | 4 | 2007 | 25 | 0.400 |
Why?
|
| Laparotomy | 3 | 2021 | 52 | 0.400 |
Why?
|
| Risk Factors | 20 | 2023 | 5338 | 0.390 |
Why?
|
| Survival Rate | 16 | 2020 | 850 | 0.380 |
Why?
|
| Blood Loss, Surgical | 3 | 2018 | 65 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 12 | 2018 | 278 | 0.340 |
Why?
|
| Liver Diseases | 2 | 2022 | 155 | 0.340 |
Why?
|
| Indiana | 10 | 2021 | 21 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2020 | 1613 | 0.330 |
Why?
|
| Bile | 6 | 2019 | 19 | 0.320 |
Why?
|
| Surgical Wound Infection | 4 | 2023 | 115 | 0.320 |
Why?
|
| Clinical Competence | 3 | 2020 | 725 | 0.320 |
Why?
|
| Pancreaticojejunostomy | 3 | 2017 | 5 | 0.320 |
Why?
|
| Sphincterotomy, Transduodenal | 3 | 2023 | 4 | 0.310 |
Why?
|
| Leptin | 8 | 2006 | 85 | 0.310 |
Why?
|
| Insulin Resistance | 3 | 2007 | 410 | 0.300 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 280 | 0.300 |
Why?
|
| Cholelithiasis | 4 | 2004 | 23 | 0.290 |
Why?
|
| Muscle, Smooth | 3 | 2019 | 134 | 0.290 |
Why?
|
| Gastrostomy | 3 | 2019 | 29 | 0.290 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.290 |
Why?
|
| Biliary Fistula | 2 | 2020 | 4 | 0.280 |
Why?
|
| Prognosis | 12 | 2020 | 1750 | 0.280 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 2460 | 0.270 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2023 | 47 | 0.270 |
Why?
|
| Prospective Studies | 12 | 2023 | 3280 | 0.260 |
Why?
|
| Splenic Artery | 2 | 2020 | 9 | 0.260 |
Why?
|
| Postoperative Care | 3 | 2018 | 123 | 0.260 |
Why?
|
| Preoperative Care | 7 | 2017 | 192 | 0.250 |
Why?
|
| Gallbladder Neoplasms | 1 | 2006 | 16 | 0.250 |
Why?
|
| Hernia, Ventral | 2 | 2020 | 25 | 0.250 |
Why?
|
| Splenectomy | 2 | 2019 | 42 | 0.250 |
Why?
|
| Gallbladder Emptying | 5 | 2006 | 5 | 0.240 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 22 | 0.240 |
Why?
|
| Necrosis | 6 | 2022 | 143 | 0.230 |
Why?
|
| Logistic Models | 6 | 2020 | 1275 | 0.220 |
Why?
|
| Intestinal Obstruction | 2 | 2020 | 53 | 0.220 |
Why?
|
| Cholesterol | 8 | 2007 | 260 | 0.220 |
Why?
|
| Aneurysm, False | 2 | 2020 | 50 | 0.220 |
Why?
|
| Insulin | 3 | 2006 | 686 | 0.210 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2023 | 12 | 0.200 |
Why?
|
| Surgical Wound | 1 | 2023 | 10 | 0.200 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2002 | 9 | 0.200 |
Why?
|
| Analgesia | 1 | 2022 | 31 | 0.190 |
Why?
|
| Cholangitis | 2 | 2019 | 11 | 0.190 |
Why?
|
| Pancreatitis, Chronic | 3 | 2020 | 19 | 0.190 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 163 | 0.190 |
Why?
|
| Dilatation, Pathologic | 2 | 2019 | 31 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 502 | 0.190 |
Why?
|
| Young Adult | 11 | 2020 | 4683 | 0.190 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2017 | 5 | 0.190 |
Why?
|
| Colonic Diseases | 1 | 2022 | 34 | 0.190 |
Why?
|
| Hyperamylasemia | 1 | 2021 | 1 | 0.190 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 10 | 0.180 |
Why?
|
| Patient Selection | 7 | 2019 | 488 | 0.180 |
Why?
|
| Disease Progression | 4 | 2022 | 1168 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 8 | 0.180 |
Why?
|
| Adolescent | 10 | 2020 | 6238 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 7 | 0.170 |
Why?
|
| Portal Vein | 2 | 2022 | 38 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2020 | 801 | 0.170 |
Why?
|
| Surgical Mesh | 1 | 2020 | 62 | 0.170 |
Why?
|
| Gastrectomy | 1 | 2020 | 40 | 0.170 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 172 | 0.170 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 7 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2022 | 182 | 0.170 |
Why?
|
| Leukocytosis | 1 | 2019 | 15 | 0.160 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2019 | 12 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 784 | 0.160 |
Why?
|
| Amylases | 2 | 2021 | 12 | 0.160 |
Why?
|
| Peritoneal Lavage | 1 | 2019 | 4 | 0.160 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2023 | 7 | 0.160 |
Why?
|
| Emergencies | 1 | 2020 | 116 | 0.160 |
Why?
|
| Survivors | 1 | 2020 | 170 | 0.160 |
Why?
|
| Activins | 1 | 2019 | 54 | 0.150 |
Why?
|
| Nurse's Role | 1 | 2020 | 120 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 78 | 0.150 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 205 | 0.150 |
Why?
|
| Lipase | 2 | 2021 | 50 | 0.150 |
Why?
|
| Constriction, Pathologic | 4 | 2020 | 129 | 0.150 |
Why?
|
| Workload | 1 | 2019 | 125 | 0.150 |
Why?
|
| Analgesia, Epidural | 1 | 2019 | 27 | 0.150 |
Why?
|
| Stomach | 1 | 2019 | 86 | 0.150 |
Why?
|
| Deoxycytidine | 2 | 2017 | 42 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 14 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 22 | 0.150 |
Why?
|
| Time Factors | 9 | 2019 | 3757 | 0.150 |
Why?
|
| Cholecystokinin | 4 | 2006 | 9 | 0.150 |
Why?
|
| DNA Fingerprinting | 1 | 2018 | 8 | 0.150 |
Why?
|
| Dietary Carbohydrates | 3 | 2007 | 61 | 0.150 |
Why?
|
| Travel | 1 | 2018 | 42 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2019 | 49 | 0.150 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 37 | 0.150 |
Why?
|
| Enteral Nutrition | 2 | 2019 | 54 | 0.150 |
Why?
|
| Cholecystectomy | 3 | 2007 | 34 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 715 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 58 | 0.150 |
Why?
|
| Gastric Bypass | 1 | 2019 | 76 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2015 | 581 | 0.140 |
Why?
|
| Cholestasis | 2 | 1996 | 65 | 0.140 |
Why?
|
| Choledocholithiasis | 1 | 2018 | 5 | 0.140 |
Why?
|
| Thrombosis | 1 | 2020 | 199 | 0.140 |
Why?
|
| Analgesics | 1 | 2019 | 102 | 0.140 |
Why?
|
| Surgeons | 1 | 2021 | 187 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2019 | 85 | 0.140 |
Why?
|
| Cross Infection | 1 | 2019 | 162 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2020 | 311 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 53 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2017 | 67 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 297 | 0.140 |
Why?
|
| Cholecystitis | 2 | 2007 | 29 | 0.140 |
Why?
|
| Hepatic Duct, Common | 1 | 2017 | 7 | 0.140 |
Why?
|
| Jejunum | 1 | 2017 | 14 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 345 | 0.140 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 34 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2017 | 337 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 149 | 0.130 |
Why?
|
| Cancer Pain | 1 | 2017 | 15 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2018 | 102 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1999 | 32 | 0.130 |
Why?
|
| Patient Safety | 1 | 2019 | 243 | 0.130 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 36 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 171 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 41 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 2 | 2015 | 42 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 316 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2017 | 64 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 66 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 474 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 972 | 0.130 |
Why?
|
| Blood Glucose | 7 | 2007 | 483 | 0.120 |
Why?
|
| Sphincter of Oddi | 3 | 2019 | 4 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 32 | 0.120 |
Why?
|
| Inpatients | 1 | 2018 | 303 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 108 | 0.120 |
Why?
|
| Databases, Factual | 5 | 2018 | 866 | 0.120 |
Why?
|
| Lipoma | 1 | 2015 | 18 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 771 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2015 | 9 | 0.120 |
Why?
|
| Financing, Organized | 1 | 2015 | 16 | 0.120 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 506 | 0.120 |
Why?
|
| Surgical Stapling | 1 | 2015 | 12 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 1 | 2015 | 9 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 3 | 2021 | 21 | 0.120 |
Why?
|
| CA-19-9 Antigen | 3 | 2014 | 10 | 0.120 |
Why?
|
| Publications | 1 | 2015 | 29 | 0.120 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1995 | 5 | 0.120 |
Why?
|
| Peptic Ulcer | 1 | 2015 | 20 | 0.120 |
Why?
|
| Splenic Vein | 1 | 2014 | 2 | 0.120 |
Why?
|
| Ampulla of Vater | 1 | 1995 | 12 | 0.120 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 35 | 0.120 |
Why?
|
| Lymph Node Excision | 2 | 2006 | 45 | 0.120 |
Why?
|
| Cystadenoma, Serous | 2 | 2005 | 4 | 0.110 |
Why?
|
| Adenoma | 1 | 2014 | 69 | 0.110 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 4 | 0.110 |
Why?
|
| Lipids | 2 | 2007 | 316 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 230 | 0.110 |
Why?
|
| Parasympatholytics | 1 | 2013 | 7 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 174 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 563 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 19 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2020 | 483 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 718 | 0.100 |
Why?
|
| Mutation | 2 | 2019 | 2607 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1084 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2015 | 198 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 70 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2015 | 154 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2012 | 25 | 0.100 |
Why?
|
| Deep Sedation | 1 | 2012 | 4 | 0.100 |
Why?
|
| Animals | 18 | 2019 | 20634 | 0.100 |
Why?
|
| Body Weight | 7 | 2007 | 377 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2019 | 863 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 242 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 447 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 865 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 10 | 2007 | 3391 | 0.090 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2012 | 41 | 0.090 |
Why?
|
| Liver | 3 | 2012 | 851 | 0.090 |
Why?
|
| Nitric Oxide Synthase | 2 | 2001 | 47 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 663 | 0.090 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2001 | 22 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2019 | 417 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 84 | 0.090 |
Why?
|
| Reoperation | 3 | 2019 | 291 | 0.090 |
Why?
|
| Crystallization | 6 | 2007 | 99 | 0.090 |
Why?
|
| Mice | 13 | 2019 | 10827 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1146 | 0.080 |
Why?
|
| Anastomosis, Surgical | 3 | 2020 | 114 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 201 | 0.080 |
Why?
|
| Dietary Fats | 2 | 2007 | 175 | 0.080 |
Why?
|
| Robotics | 1 | 2010 | 87 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 133 | 0.080 |
Why?
|
| Endosonography | 3 | 2017 | 26 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 18 | 0.070 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2006 | 3 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 372 | 0.070 |
Why?
|
| Operative Time | 2 | 2019 | 92 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2007 | 220 | 0.070 |
Why?
|
| Cholesterol, Dietary | 2 | 2006 | 29 | 0.070 |
Why?
|
| Adipose Tissue | 2 | 2007 | 295 | 0.070 |
Why?
|
| Cholangitis, Sclerosing | 2 | 1999 | 13 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2007 | 43 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2019 | 2071 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 730 | 0.070 |
Why?
|
| Azetidines | 1 | 2007 | 8 | 0.070 |
Why?
|
| Morbidity | 2 | 2020 | 113 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 35 | 0.070 |
Why?
|
| Statistics, Nonparametric | 4 | 2009 | 214 | 0.070 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2007 | 2 | 0.070 |
Why?
|
| Resistin | 1 | 2007 | 6 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2019 | 345 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2019 | 387 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 33 | 0.060 |
Why?
|
| Midwestern United States | 1 | 2006 | 25 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 935 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 50 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 357 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2021 | 874 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 63 | 0.060 |
Why?
|
| Gene Expression | 2 | 2019 | 839 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 26 | 0.060 |
Why?
|
| Mice, Obese | 4 | 2006 | 80 | 0.060 |
Why?
|
| United States | 4 | 2020 | 7828 | 0.060 |
Why?
|
| Dissection | 1 | 2005 | 48 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 319 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1121 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2005 | 79 | 0.060 |
Why?
|
| Cystadenoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 217 | 0.060 |
Why?
|
| Pylorus | 1 | 2004 | 10 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 2167 | 0.050 |
Why?
|
| Acetylcholine | 4 | 2006 | 44 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 60 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2011 | 2566 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 1 | 2003 | 4 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2017 | 72 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 88 | 0.050 |
Why?
|
| Recurrence | 3 | 2014 | 643 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 1543 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 525 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 122 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 45 | 0.050 |
Why?
|
| Stents | 1 | 2007 | 491 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 2019 | 202 | 0.050 |
Why?
|
| Diet | 1 | 2006 | 524 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 537 | 0.050 |
Why?
|
| Acute Disease | 1 | 2023 | 672 | 0.050 |
Why?
|
| Ileum | 1 | 2001 | 22 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1396 | 0.050 |
Why?
|
| Decompression | 1 | 2021 | 1 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2021 | 6 | 0.040 |
Why?
|
| Organ Size | 3 | 2007 | 172 | 0.040 |
Why?
|
| North America | 2 | 2012 | 111 | 0.040 |
Why?
|
| Gastric Fistula | 1 | 2020 | 4 | 0.040 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2020 | 7 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 156 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 25 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 35 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 422 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 893 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 102 | 0.040 |
Why?
|
| Genotype | 1 | 2002 | 664 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 70 | 0.040 |
Why?
|
| Triglycerides | 3 | 2007 | 244 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 47 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 97 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 768 | 0.040 |
Why?
|
| Cachexia | 1 | 2019 | 9 | 0.040 |
Why?
|
| Activin Receptors, Type II | 1 | 2019 | 9 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 41 | 0.040 |
Why?
|
| Heparin | 1 | 2020 | 116 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 159 | 0.040 |
Why?
|
| Colectomy | 1 | 2020 | 108 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 33 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 180 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1999 | 17 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 38 | 0.040 |
Why?
|
| Lymphoma | 1 | 2000 | 102 | 0.040 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 26 | 0.040 |
Why?
|
| Failure to Thrive | 1 | 2019 | 8 | 0.040 |
Why?
|
| Centralized Hospital Services | 1 | 2018 | 6 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 111 | 0.040 |
Why?
|
| Genes, ras | 1 | 1998 | 27 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 335 | 0.040 |
Why?
|
| Nurses | 1 | 2020 | 108 | 0.040 |
Why?
|
| Genes, p53 | 1 | 1998 | 52 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 279 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 93 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 66 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 35 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 1223 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 169 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1560 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 495 | 0.040 |
Why?
|
| Progesterone | 1 | 1999 | 163 | 0.040 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2017 | 2 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2017 | 5 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 151 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 134 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2017 | 20 | 0.040 |
Why?
|
| Stem Cell Factor | 1 | 2017 | 26 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 488 | 0.030 |
Why?
|
| Anoctamin-1 | 1 | 2017 | 16 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 92 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 165 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 98 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2017 | 9 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 232 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 738 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 536 | 0.030 |
Why?
|
| Failure to Rescue, Health Care | 1 | 2017 | 5 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 110 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2180 | 0.030 |
Why?
|
| Random Allocation | 2 | 2012 | 199 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2007 | 56 | 0.030 |
Why?
|
| Phospholipids | 2 | 2007 | 81 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 451 | 0.030 |
Why?
|
| Choledochal Cyst | 1 | 1996 | 3 | 0.030 |
Why?
|
| Universities | 1 | 2017 | 158 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 281 | 0.030 |
Why?
|
| Dogs | 2 | 2012 | 325 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 519 | 0.030 |
Why?
|
| Surgery Department, Hospital | 1 | 2015 | 21 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2017 | 176 | 0.030 |
Why?
|
| Neuropeptide Y | 2 | 2006 | 13 | 0.030 |
Why?
|
| Jejunostomy | 2 | 2010 | 7 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1465 | 0.030 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 15 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 46 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 118 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 59 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1355 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 6 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 41 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 99 | 0.030 |
Why?
|
| Neurotransmitter Agents | 2 | 2004 | 42 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 78 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2004 | 149 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 442 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2006 | 410 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 196 | 0.020 |
Why?
|
| Sciuridae | 2 | 2001 | 3 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 1649 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1539 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 734 | 0.020 |
Why?
|
| Ligation | 1 | 2011 | 39 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 210 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 913 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 736 | 0.020 |
Why?
|
| Algorithms | 2 | 2010 | 1002 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2001 | 319 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 129 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 65 | 0.020 |
Why?
|
| Florida | 1 | 2010 | 48 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2001 | 608 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 568 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 608 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 52 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 318 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3033 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 311 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 138 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cholesterol Esters | 1 | 2007 | 10 | 0.020 |
Why?
|
| Poverty | 1 | 2010 | 296 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 71 | 0.020 |
Why?
|
| Viscera | 1 | 2007 | 10 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 62 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 89 | 0.020 |
Why?
|
| Cholinergic Agents | 1 | 2006 | 9 | 0.020 |
Why?
|
| Decision Making | 1 | 2010 | 407 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1118 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 152 | 0.020 |
Why?
|
| Butter | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 74 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 189 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2005 | 18 | 0.010 |
Why?
|
| Enema | 1 | 2005 | 14 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 302 | 0.010 |
Why?
|
| Spleen | 1 | 2005 | 483 | 0.010 |
Why?
|
| Vacuoles | 1 | 2003 | 26 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 1200 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 934 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2003 | 106 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 860 | 0.010 |
Why?
|
| Contrast Media | 1 | 2005 | 424 | 0.010 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide | 1 | 2001 | 1 | 0.010 |
Why?
|
| Nitroarginine | 1 | 2001 | 2 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2001 | 17 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2001 | 7 | 0.010 |
Why?
|
| Iron, Dietary | 1 | 2001 | 9 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2001 | 140 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2001 | 46 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 135 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 27 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 79 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 86 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 99 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 68 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 621 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 373 | 0.010 |
Why?
|
| West Virginia | 1 | 1998 | 6 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 221 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 409 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1999 | 102 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 1999 | 215 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 304 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 264 | 0.010 |
Why?
|
| Child | 1 | 1999 | 4522 | 0.000 |
Why?
|